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Background: Currently the combined cognitive-behavioral and pharmacological treatment is the best option to quit
smoking, although success rates remain moderate. This study aimed to identify predictors of continuous abstinence
in an assisted smoking cessation program using combined treatment. In particular, we analyzed the effects of
socio-demographic, smoking-, and treatment-related variables. In addition, we analyzed the effect of several risk
factors on abstinence, and estimated a model of risk for smoking relapse.
Methods: Participants were 125 workers at the University of Granada (50 males), with an average age of 46.91 years
(SD = 8.15). They were recruited between 2009 and 2013 at an occupational health clinic providing smoking cessation
treatment. Baseline measures included socio-demographic data, preferred brand of cigarettes, number of years
smoking, use of alcohol and/or tranquilizers, past attempts to quit, Fargerström Test for Nicotine Dependence,
Smoking Processes of Change Scale, and Coping with Withdrawal Symptoms Interview. Participants were invited to a
face-to-face assessment of smoking abstinence using self-report and cooximetry hemoglobin measures at 3, 6, and
12 months follow-up. The main outcome was smoking status coded as “relapse” versus “abstinence” at each follow-up.
Kaplan-Meier survival analysis was performed to estimate the probability of continued abstinence during 12 months
and log-rank tests were used to analyze differences in continued abstinence as a function of socio-demographic,
smoking-, and treatment-related variables. Cox regression was used to analyze the simultaneous effect of several
risk factors on abstinence.
Results: Using alcohol and/or tranquilizers was related to shorter abstinence. Physical exercise, the number of treatment
sessions, performance of treatment tasks, and coping with withdrawal symptoms were related to prolonged abstinence.
In particular, failure to perform the treatment tasks tripled the risk of relapse, while lack of coping doubled it.
Conclusions: Our results show that physical exercise, performance of treatment-related tasks, and effective coping with
withdrawal symptoms can prolong abstinence from smoking. Programs designed to help quit smoking can benefit from
the inclusion of these factors.
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Tobacco consumption remains the number one prevent-
able cause of morbidity and mortality, responsible for 31%
of lung cancer cases. Other types of cancer associated with
tobacco consumption are lip, mouth, pharynx, larynx,
esophagus, bladder, and kidney cancer. Further, exposure
to environmental (i.e., second hand) tobacco smoke
increases the risk of lung cancer, as well as the risk of
suffering respiratory, cardiovascular, and other chronic
diseases [1]. Despite several decades of falling smoking
prevalence rates, the National Spanish Health Survey [2]
now shows that this decline has stalled, with 27.9% of men
and 20.2% of women over age 16 smoking daily. Currently
the combined cognitive-behavioral and pharmacological
treatment is the best option to quit smoking [3-8]. General
population surveys show that about 70% of smokers would
like to quit and about 30-40% try to do so, but the propor-
tion of those who succeed is less than 5% [9-11]. Recent
studies have identified a number of variables associated
with success at quitting smoking [12-19]. Among these are
socio-demographic variables such as age, gender, education
level, and occupation. To illustrate, younger men (aged
22-38 years) are more likely to continue smoking than
older men [18] and women are less likely to quit than men
[13]; education level and occupation have not been associ-
ated with quitting success [16].
Other factors investigated extensively are the severity
of tobacco dependence and its relation to treatment out-
comes. In particular, the number of cigarettes, the intensity
of tobacco dependence, and alcohol consumption decrease
the probability of quitting [15-17]. Treatment-related
variables can also influence quitting success. For example,
past attempts to quit predicted abstinence during the first
week and sustained abstinence during 6 months in a sec-
ond attempt to quit [15]. Another factor that can influence
treatment adherence is the number of treatment sessions
[4,19]. For example, having completed more than four
treatment sessions and performed treatment tasks pre-
dicted abstinence at 6 months [17]. Finally, the motivation
to change has also been related to quitting success [20].
Treatment adherence is defined as the degree to which
the person's behavior follows health recommendations.
It includes the patient's ability to attend scheduled
appointments, take medications as indicated, make the
recommended changes in lifestyle, and complete the
laboratory studies or tests requested [21]. There are
several methods to measure treatment adherence and
each of them has some limitations. Hence, several
methods should be used simultaneously in order to
gather as much information as possible. For instance, it
has been proposed to use three variables to assess adher-
ence: the completion of tasks assigned during treatment,
the number of completed treatment sessions, and the
extent of coping with withdrawal symptoms [22]. Finally,some studies emphasize the role of physical exercise in
coping with craving and withdrawal symptoms (depressed
mood, negative affect, insomnia, stress, and weight gain)
[23-25]. For instance, performing moderate exercise
reduces craving and this effect is maintained for more
than 20 minutes after exercise completion [26,27].
The objective of this study was to identify predictors of
continuous abstinence during 12 months in an assisted
smoking cessation program. In particular, we investigated
the influence of socio-demographic variables (age, gender,
education level, and occupation), smoking-related vari-
ables (cigarette brand, nicotine concentration mg per
cigarette, number of cigarettes smoked daily, nicotine
dependence, years of smoking, use of alcohol and/or tran-
quilizers) and treatment-related variables (past attempts
to quit, compliance with the pharmacological therapy,
performance of treatment tasks, number of treatment
sessions, coping with withdrawal symptoms, and physical
exercise). Finally, we analyzed the simultaneous effect of
several risk factors on abstinence and estimated a model
of risk for smoking relapse.
Methods
Participants
Participants were 125 workers at the University of Granada
(50 men and 75 women) with a mean age of 46.91 years
(SD = 8.15). They were recruited between 2009 and 2013 at
an occupational health clinic providing smoking cessation
treatment. Participants smoked a mean number of 19.86
(SD = 8.95) cigarettes daily. The mean score on the
Fagerström test for nicotine dependence was 4.62 (SD =
2.24). Participants entered the study if they were 18 years
of age or older, had an employment contract with the
University of Granada, wanted to voluntarily participate in
the treatment, and correctly filled in the pre-treatment
evaluation measures. Participants were excluded if they
were diagnosed with a serious mental disorder (bipolar
and/or psychotic disorder, etc.), had a concurrent depend-
ence on other substances (cocaine, heroin, alcohol, etc.),
or were regularly taking medications that were incompat-
ible with the pharmacological treatment used in the
therapy. Participants were assessed at baseline with the
measures outlined below. As part of the treatment patients
underwent cognitive-behavioral therapy, which included
the performance of tasks at home, and pharmacological
therapy with varenicline. Participants were informed about
the aims of the study and provided signed informed
consent. Ethical approval was obtained from the Ethics
Committee, Research University of Granada, Spain.
Procedure
An initial evaluation of the smokers was performed in a
single session at the beginning of the program, in which
the instruments described below were administered. The
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sessions of the program were implemented individually.
The program consisted of three phases. The first phase
included a personalized number of sessions until abstinence
was reached. During the first phase the cognitive-behavioral
therapy was initiated by working towards developing
stimulus control and self-control, and reducing tobacco
consumption. Once the smoker had reduced tobacco
consumption by 80%, pharmacological treatment with
varenicline was started. We chose this scheme for two rea-
sons. First, this was a way to ensure that the participant
was sufficiently motivated to receive the free pharmaco-
logical treatment and quit smoking. Second, this way the
participant starts to develop his or her self-control and
management of symptoms. Varenicline is a nicotinic
receptor partial agonist that effectively aids smoking cessa-
tion. The treatment starts with a daily dose of 0.5 mg for
three days, and increases to a dose of 1 mg twice a day
until the end of the treatment. The duration of the treat-
ment with varenicline was 12 weeks. Adherence was de-
fined as accurately following the prescribed regimen.
Prescription of varenicline was administered in line with
the Food and Drug Administration’s guidelines [28,29]. The
cost of the medication was covered by the Prevention
Service (Area Labor Medicine) of the University of Granada.
If the participants did not reach abstinence, they abandoned
the program. Participants who reached abstinence pro-
ceeded to the second phase of the program which consisted
of 6 sessions and aimed to maintain abstinence. It included
training in problem solving, coping, and behaviors alterna-
tive to smoking. Participants also performed tasks at home.
These tasks included reporting their smoking behavior,
cravings, coping, and problem solving. The third phase
consisted of three follow-up sessions (at 3, 6, and 12
months). Participants were telephonically contacted by an
independent assessor (blind to the study purpose and
methods) at each endpoint (3, 6 and 12 months after the
start of the program). The purpose was to monitor their
compliance with the treatment and their willingness to
participate in the follow-up face-to-face assessments of
smoking abstinence. Abstinence was assessed with a self-
report of smoking behavior which was cross-validated with
measurement of patients’ co-oximetry hemoglobin levels.
Participants’ outcomes were coded as “relapse” or “abstin-
ence”. Abstinence was defined as not having smoked even
once since the day the participant quit after gradual reduc-
tion of nicotine intake and pharmacological treatment.
Relapse was defined as having smoked for 7 consecutive
days in the past 3, 6 and 12 months, respectively [30-32].Instruments
Semi-structured interview for smokers [33]. This instru-
ment provides information about socio-demographic data,preferred brand of cigarettes, number of years smoking,
usage of other substances, and past attempts to quit.
Fargerström Test for Nicotine Dependence [34]. This
instrument evaluates the intensity of physical addiction to
nicotine and has a consistent factorial structure [35]. In
this study we used the Spanish version of the test [36].
Smoking Processes of Change Scale (SPC) [37,38]. This
questionnaire measures 10 basic processes of change. Par-
ticipants indicated the frequency with which they have en-
gaged in or experienced 40 activities or events within the
last month on a 5-point Likert scale from (1) never to (5)
repeatedly. This instrument has good psychometric proper-
ties. In this research we used the Spanish version of the
instrument [39].
Coping with Withdrawal Symptoms Interview (CWSI).
This instrument was designed specifically for this research.
Each item had 4 response alternatives, on a 4-point Likert
scale from (1) never to (4) repeatedly. Smokers were asked
about (1) craving in the past month, (2) coping with
craving, (3) presence of anxiety, (4) depression, (5) sleeping
problems, (6) eating problems (excess appetite), (7) phys-
ical problems like stomach pain as a result of drug therapy,
or other physical problems, (8) whether they had done
physical exercise in order to cope with withdrawal symp-
toms and (9) whether they perceived any benefits after
quitting smoking. Exercise was measured following the
criteria of the International Physical Activity Questionnaire
(IPAQ) [40,41]. In particular, participants answered 9 ques-
tions on a 5-point Likert scale about the intensity, fre-
quency, and duration of physical activity they did in the
past month. Based on their averaged responses to these
questions, participants were classified in three groups: fre-
quent exercise, moderate exercise, and inactive. Based on
their responses on all interview questions, participants
were classified into three coping groups: lack of coping
and recognition of the problem, i.e., ineffective coping
(score < 4), moderate coping (score 6 to 12), and effective
coping (score 13 to 17).
Statistical analysis
Discrete-time survival methods were used to analyze
how the variation in risk of smoking relapse over time
was related to the socio-demographic, smoking-, and
treatment-related variables. The survival time of partici-
pants who did not smoke during the observation period
was set to the end of the data collection window [42].
Event status was coded as 0 = relapse (smoked prior to
termination time) or 1 = still abstinent at termination
time. A predictor was retained in the model if it improved
the overall goodness of fit of the model. The effects of the
continuous predictors were displayed by plotting survival
functions using Kaplan–Meier graphs [43] and estimating
the median life-time, the time at which half the sample
had experienced the event and half had not [44]. Last,
Table 1 Number of participants classified as abstinent vs.
in relapse
Time Abstinence Relapse % Abstinence rate
1- month 75 50 60%
3 –month 70 55 56%
6- month 56 69 44.8%
12- month 45 80 36%
Abstinence was defined as not having smoked even once since the day the
participant quit after gradual reduction of nicotine intake and pharmacological
treatment. Relapse was defined as having smoked for 7 consecutive days in
the respective period.
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calculate the hazard rate ratios [14,45,46]. The survival
analysis was conducted with the SPSS software package.Results
Abstinence rates
At 1-month follow-up, 75 participants had maintained ab-
stinence during treatment. Therefore, the abstinence rate
was 60%. At 3-month follow-up, 70 participants had main-
tained abstinence during treatment (abstinence rate = 56%).
At 6-month follow-up, 56 participants had maintained
abstinence during treatment (abstinence rate = 44.8%). At
the 12-month follow-up, 45 participants had maintained
abstinence during treatment (abstinence rate = 36%) (see
Table 1).Socio-demographic variables
Survival analysis results (Table 2) revealed that the
abstinence duration was not different across groupsTable 2 Survival analysis results: effects of socio-demographi
Variables Abstine
Sample size Number Rate
Age
27-37 16 11 68.8%
38-48 54 41 75.9%
49-63 55 43 78.2%
Gender
Male 50 39 78%
Female 75 56 74.7%
Education
Elementary school 63 47 74.6%
College degree 43 31 72.1%
Ph.D. 19 17 89.5%
Occupation
Janitorial 18 15 83.3%
Administrative and service personnel 80 58 72.5%
Teachers and researchers 27 22 81.5%determined by socio-demographic characteristics (age,
gender, education level, and occupation).
Smoking-related variables
Survival analysis results (Table 3) showed that the abstin-
ence duration for the different categories of the variable
use of alcohol and/or tranquillizers differed significantly
(Log Rank =17.679; p =0.001), i.e., using another substance
had a significant influence on the probability to remain
abstinent. Figure 1 shows the survival curve depending on
the use of another substance. The group that used no other
substance showed greater survival than the group with
alcohol use; the group with alcohol use in turn showed
greater survival than the group that used tranquilizers. The
p-values in Table 3 indicate that there were no significant
differences in abstinence duration with respect to the vari-
ables cigarettes brand, nicotine concentration mg/cigarette,
number of cigarettes smoked daily, score on the Fagerström
test, and years of smoking.
Treatment-related variables
Survival analysis results (Table 4) revealed that the follow-
ing variables had a significant influence on survival time:
performance of treatment tasks, Log Rank = 68.330,
p = 0.001, number of treatment sessions, Log Rank = 8.283,
p = 0.041, coping with withdrawal symptoms, Log Rank =
49.750, p = 0.000, and physical exercise, Log Rank =
23.376, p = 0.001. Figures 2, 3 and 4 illustrate the survival
curves for abstinence duration for the different levels of
these variables. In particular, Figure 2 shows that par-
ticipants in the effective task performance and moderate
task performance groups have a better survival curvec variables
nce 95% IC Log rank
(Mantel-Cox)
p
s Mean Standard error
6.73 1.54 3.71- 9.74 1.833 .400
8.32 .73 6.89 - 9.75
7.07 .72 5.66 - 8.48
7.85 .77 6.34 - 9.35 .247 .619
7.38 .63 6.14 - 8.61
7.06 .69 5.70 - 8.42 2.255 .324
8,65 .81 7.07- 10.22
7,00 1.23 4.58 - 9.42
7.40 1.23 4.99 - 9.80 1.318 .517
7.95 .62 6.72- 9.17
6.68 1.03 4.66- 8.70
Table 3 Survival analysis results: effects of smoking-related variables
Variables Abstinence 95% IC Log rank
(Mantel-Cox)
p
Sample size Number Rates Mean Standard error
Cigarette brand
Blonde 105 80 85% 7.54 .54 6.48 - 8.59 3.931 .140
Black 12 9 75% 5.90 1.35 3.25 - 8.53
Rolling 8 6 73.1% 10.50 1.50 7.56 - 13.44
Nicotine concentration mg per cigarette
<1 23 20 85% 6.45 1.10 4.29 - 8.61 1.619 .44
>1 < 1.5 99 72 75% 7.90 .56 6.82 - 8.99
>1.5 2 3 3 73.1% 7.00 2.65 1.81 - 12.19
Number of cigarettes smoked daily
< 10 20 17 85% 7.94 1.14 5.71 - 10.17 .186 .980
>10 < 20 72 54 75% 7.44 .64 6.19 - 8.70
>20 < 30 26 19 73.1% 7.58 1.13 5.37 - 9.78
>30 7 5 71.4% 7.60 2.69 2.32 - 12.88
Fagerström test score
<6 99 77 77.8% 7.69 .54 6.63 - 8.75 .296 .586
>7 26 18 69.2% 7.06 1.14 4.83 - 9.28
Years of smoking
< 10 years 14 12 85.7% 7.17 1.47 4.28 - 10.05 2.560 .464
< 20 years 28 19 67.9% 8.26 1.09 6.12 - 10.40
< 30 years 40 33 82.5% 8.21 .82 6.60 - 9.83
> 30 years 43 31 72.1% 6.61 .84 4.98 - 8.25
Use of alcohol and/or tranquilizers
Neither 116 87 75% 8.07 .50 7.10 - 9.04 17.679 .001
Alcohol 7 7 100% 2.29 .71 .89 - 3.69
Tranquilizers 2 1 50% 1.00 .00 1.00 - 1.00
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shows that participants who completed 16-20 treatment
sessions had a better survival curve than those who
completed 11-15, 6-10 or 1-5 treatment sessions.
Figure 3 shows that participants who were classified in
the groups effective coping and moderate coping had a
better survival curve than those classified into ineffect-
ive coping. Figure 4 shows that participants in the
frequent and moderate exercise groups have a better
survival curve than participants who were classified as
never engaging in physical exercise. Past attempts to
quit and compliance with the pharmacological therapy
had no significant influence on abstinence duration.
Cox regression analysis
We performed a Cox regression analysis to identify risk
factors associated with the probability of survival. We fitted
a model including all factors related to tobacco consump-
tion and treatment which were significant in the survivalanalysis. We included two additional quantitative variables:
processes of change and number of days it took for the
smoker to achieve abstinence. Table 5 shows that the
variables performance of treatment tasks and coping with
withdrawal symptoms were significant (p = 0.01 and 0.013,
respectively). The negative sign of the beta-coefficients (B)
indicates the direction of the relationship; i.e., these vari-
ables are protective factors for abstinence from smoking
(Hazard ratio <1). Processes of change, days to achieve
abstinence, other drug used, number of treatment sessions,
and physical exercise were not significant (p >0.05) in the
regression model. Table 6 shows a comparison between
the levels of the variable performance of treatment tasks.
Specifically, the group which did not perform the tasks had
3 times higher risk of smoking relapse than the group
performing tasks moderately [Hazard ratio; (H.R = 3.032)].
No differences in survival are observed between the group
performing tasks moderately and the group performing
tasks effectively. Also Table 6 shows a comparison between
Figure 1 Survival curve depending on the use of another substance.
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Specifically, the group which coped ineffectively had 2.4
times higher risk of smoking relapse than the group which
coped moderately [Hazard ratio (H.R = 2.410)]. No differ-
ences in survival were observed between participants who
coped moderately and effectively.
Discussion and conclusions
The aim of this study was to identify predictors of continu-
ous abstinence in an assisted smoking cessation program
using combined cognitive-behavioral and pharmacological
therapy. In particular, we investigated the influence of
socio-demographic, smoking-, and treatment-related vari-
ables. We analyzed the effect of several risk factors on
abstinence and modeled the probability of remaining
abstinent at follow-up. In particular, we utilized baseline
psychometric assessments and predicted smoking status at
three endpoints: 3, 6 ,and 12 months after the start of the
program.
Results from the survival analysis revealed that socio-
demographic variables were not related to abstinence.
These results are in line with some previous studies
[15,16]. However, other studies [5,20] have found that
socio-demographic variables, smoking habits, past at-
tempts to quit, and motivation for change are associated
with smoking relapse. These discrepancies may be due to
the fact that smokers are a heterogeneous group [12].We found that using alcohol and/or tranquilizers in-
fluenced abstinence. In particular, patients who did not
use any substances had better survival curves than
those who consumed alcohol. Further, patients who
were using tranquilizers had an even worse survival
curve than those who consumed alcohol. These results
are in line with previous findings showing that alcohol
and tranquilizers can be a coping response to nicotine
withdrawal [14]. The brand of cigarettes, nicotine con-
centration mg/cigarette, number of cigarettes smoked
daily, score on the Fagerström test, and years of smok-
ing were unrelated to abstinence. This lack of effects is
inconsistent with results from previous studies where
nicotine dependence and motivation for change predicted
quitting success and high scores on the Fageström test
and the number of previous attempts to quit smoking pre-
dicted abstinence one week and 6 months post-treatment
[12,15,19].
Most importantly, our results showed that performance
of treatment tasks, the number of treatment sessions,
coping with withdrawal symptoms, and physical exercise
had a significant influence on the duration of abstinence.
While the effect of number of treatment sessions has been
established by previous research [4,9,19], this is the first
study to our knowledge to link effectiveness of treatment
task performance to continued abstinence one year after
the start of treatment.
Table 4 Survival analysis results: effects of treatment-related variables
Variables Abstinence 95% IC Log rank
(Mantel-Cox)
p
Sample size Number Rates Mean Standard error
Past attempts to quit (N)
0 31 19 96.3% 7.21 1.13 4.99 - 9.43 4.415 .220
<2 79 63 79.7% 7.79 .59 6.64 - 8.95
<7 12 11 91.7% 7.91 1.51 4.95 - 10.87
>7 3 2 91.7% 2.00 1.00 .04 - 3.96
Compliance with the pharmacological therapy
Not 33 8 24.24% 7.38 1.83 3.79 -10.97 .008 .931
Yes 92 87 94.56% 7.59 .507 6.59 - 8.58
Performance of treatment tasks
Not 61 32 52.5% 2.81 .57 1.69 - 3.93 68.330 .001
Moderate 26 26 100% 8.04 .79 6.50 - 9.58
Yes 38 37 97.4% 11.35 .31 10.7 - 11.96
Number of treatment sessions
1-5 43 23 53.5% 6.78 1.03 4.77 – 8.80 8.283 .041
6-10 60 52 86.7% 8.71 .63 7.52 – 9.91
11-15 14 12 85.7% 6.08 1.38 3.37 - 8.80
16-20 8 8 100% 4.63 1.72 1.25 - 8.00
Coping with withdrawal symptoms
Ineffective 49 25 51% 2.76 .51 1.77 - 3.76 49.750 .001
Moderate 46 41 89.1% 8.17 .73 6.75 - 9.59
Effective 30 29 96.7% 10.86 .48 9.92 - 11.80
Physical exercice
Never 49 28 57.1% 4.18 .77 2.67 - 5.69 23.376 .001
Moderate 42 33 78.6% 8.85 .74 7.41 - 10.29
Frequent 34 34 100% 9.12 .75 7.65 - 10.59
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tasks effectively were abstinent for longer than partici-
pants who performed them less effectively. In particular,
the group that did not perform the tasks had a 3 times
larger risk of relapse. Our results suggests that giving
“homework” to smokers in the form of regularly reporting
on their smoking behavior, cravings, or coping behavior,
should be implemented in programs designed to help quit
smoking. Further research is needed to investigate what
factors are related to performing such tasks effectively and
how they should be implemented in order to maximize
completion rates.
Both effective and moderately effective coping with with-
drawal symptoms resulted in longer abstinence than coping
ineffectively. In particular, the group of participants classified
as coping ineffectively had a 2.4 times higher risk of relapse
than the group that coped moderately. To our knowledge
this is the first study to assess the effectiveness of coping
with withdrawal symptoms and its impact on the durationof abstinence. Our results suggest that coping effectively
with withdrawal symptoms can increase quitting success.
Future research should identify how we can help smokers
in a quitting program to develop effective coping strategies
and thus increase their chances of staying abstinent.
Regarding physical exercise, the results showed that par-
ticipants who never did any physical exercise were abstin-
ent for a shorter period of time than participants who
engaged in physical exercise moderately or frequently.
Engaging in physical exercise frequently rather than only
moderately resulted in no additional benefits. These
results confirm that physical exercise can be an effective
strategy to cope with withdrawal symptoms [23-25].
Finally, our study indicates that moderate exercise can be
as effective as intensive exercise in prolonging abstinence.
Past attempts to quit and compliance to the pharmaco-
logical therapy had no significant influence on abstinence
duration. In contrast to our results, past studies found that
these factors were related to abstinence, motivation to
Figure 2 Survival curve depending on performance of treatment tasks.
Figure 3 Survival curve depending on coping with withdrawal symptoms.
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Figure 4 Survival curve depending on physical exercise.
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these differences may be due to the fact that our partici-
pants were all highly motivated to quit smoking. Future
research can investigate this proposition by comparing
participants high and low in motivation.
One limitation of our study is that all participants were
employees of the University of Granada and had homoge-
neous socio-demographic characteristics (for example, all
were employed, with high level of motivation). This makes
it difficult to generalize our results to the general popula-
tion. Further, the number of patients who used alcohol
and/or tranquillizers in this study was rather small. How-
ever, an advantage of this study setting was that subjects
attended all the follow-up visits, while usually smoking
cessation studies are characterized by high lost-to-follow-Table 5 Results from Cox regression analysis on the
probability to remain abstinent at 12 months follow-up
Variables B p H.R 95.0% IC
Motivation for change -.018 .778 .982 .868 - 1.112
Days to achieve abstinence -.004 .519 .996 .984 - 1.008
Use of alcohol and/or tranquilizers .573 .107 1.773 .883 - 3.561
Number of treatment sessions .042 .134 1.043 .987 - 1.103
Physical exercice -.021 .889 .979 .725 - 1.322
Performance of treatment tasks -.547 .001 .579 .422 - .794
Coping with withdrawal symptoms -.070 .013 .933 .882 - .986up rates. This surprising result could be due to the fact that
participants were in a controlled environment (Occupa-
tional Medicine Area, Prevention Service at the University
of Granada). In particular, they were in continuous contact
with the service regarding the smoking cessation program
and regular health checks. This could have prevented any
potential drop out.
In summary, the consumption of other drugs (alcohol
and/or tranquilizers) shortened abstinence, while physical
exercise, performance of treatment tasks, and coping with
withdrawal symptoms prolonged abstinence. In particular,
failure to perform the treatment tasks tripled the risk of
relapse, while lack of coping doubled it. These results
suggest that programs designed to help quitting smoking
can benefit from the inclusion of these factors.Table 6 Comparison between the levels of the variables
performance of treatment tasks and coping with
withdrawal symptoms in Cox regressions
Variables B p H.R 95.0% IC
Performance of treatment tasks .003
Ineffective - Moderate 1.109 .001 3.032 1.601 - 5.743
Effective - Moderate .321 .231 1.378 .815 - 2.330
Coping with withdrawal symptoms .051
Ineffective - Moderate .880 .016 2.410 1.178 - 4.930
Effective - Moderate .206 .409 1.229 .753 - 2.006
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